Who to call at Cartesian Therapeutics, Inc., and when
Fundz watches for the moments Cartesian Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Cartesian Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cartesian Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cartesian Therapeutics, Inc.. With Fundz connected, it knows.
Cartesian Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
selectabio.com2 executive changes at Selecta Biosciences in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Cartesian Therapeutics eliminated the Chief Scientific Officer position and terminated Christopher Jewell, Ph.D. without cause, effective November 14, 2025. Under a separation agreement signed October 20, 2025, he receives 12 months' salary and a pro-rated bonus in exchange for a release of claims.
Key Takeaways
The Chief Scientific Officer role was eliminated and the CSO, Christopher Jewell, Ph.D., was terminated without cause, with both actions effective November 14, 2025.
Dr. Jewell signed a separation agreement and release on October 20, 2025, releasing the company and related parties from claims arising through November 14, 2025.
2 more takeaways
Related Filings (8)
8 more filings from Cartesian Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Cartesian Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.